• Junshi Biosciences completed first-patient dosing in a Phase 3 trial of JS207 with JS007 on Oct. 29, 2026.
• The trial compares the combination with toripalimab plus bevacizumab as a first-line treatment for advanced hepatocellular carcinoma.
• Planned enrollment is 560 patients, with overall survival and progression-free survival as primary endpoints.
• Phase 2 results were presented at the European Society for Medical Oncology Congress in October 2026.
• Those results showed strong anti-tumor activity; the combination was well tolerated.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Junshi Biosciences Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290704PRIMZONEFULLFEED9856020) on October 29, 2026, and is solely responsible for the information contained therein.